Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Impact · against what's priced in

Altimmune's receipt of FDA Breakthrough Therapy Designation and alignment on Phase 3 trial parameters significantly de-risks the regulatory path for pemvidutide in MASH. The potential for accelerated approval based on biopsy endpoints creates a tangible catalyst for faster revenue generation than previously expected.

ALT+0.70

No priced-in read yet